Heparanase—A single protein with multiple enzymatic and nonenzymatic functions
Proteoglycan Research · 2023
DOI: 10.1002/pgr2.6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Proteoglycan Research, 2023. Verfasst von Israel Vlodavsky und 5 weiteren Autor:innen. Beteiligte Einrichtung: Technion Integrated Cancer Center, Technion Rappaport Faculty of Medicine Haifa Israel. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Israel Cancer Association, Israel Science Foundation.
Abstract (Originalsprache)
Heparanase (Hpa1) is expressed by tumor cells and cells of the tumor microenvironment and functions extracellularly to remodel the extracellular matrix (ECM) and regulate the bioavailability of ECM‐bound factors, augmenting, among other effects, gene transcription, autophagy, exosome formation, and heparan sulfate (HS) turnover. Much of the impact of heparanase on tumor progression is related to its function in mediating tumor‐host crosstalk, priming the tumor microenvironment to better support tumor growth, metastasis, and chemoresistance. The enzyme appears to fulfill some normal functions associated, for example, with vesicular traffic, lysosomal‐based secretion, autophagy, HS turnover, and gene transcription. It activates cells of the innate immune system, promotes the formation of exosomes and autophagosomes, and stimulates signal transduction pathways via enzymatic and nonenzymatic activities. These effects dynamically impact multiple regulatory pathways that together drive tumor growth, dissemination, and drug resistance as well as inflammatory responses. The emerging premise is that heparanase expressed by tumor cells, immune cells, endothelial cells, and other cells of the tumor microenvironment is a key regulator of the aggressive phenotype of cancer, an important contributor to the poor outcome of cancer patients and a valid target for therapy. So far, however, antiheparanase‐based therapy has not been implemented in the clinic. Unlike heparanase, heparanase‐2 (Hpa2), a close homolog of heparanase (Hpa1), does not undergo proteolytic processing and hence lacks intrinsic HS‐degrading activity, the hallmark of heparanase. Hpa2 retains the capacity to bind heparin/HS and exhibits an even higher affinity towards HS than heparanase, thus competing for HS binding and inhibiting heparanase enzymatic activity. It appears that Hpa2 functions as a natural inhibitor of Hpa1 regulates the expression of selected genes that maintain tissue hemostasis and normal function, and plays a protective role against cancer and inflammation, together emphasizing the significance of maintaining a proper balance between Hpa1 and Hpa2.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Technion Integrated Cancer Center, Technion Rappaport Faculty of Medicine Haifa Israel.
- Department of Pathology University of Alabama at Birmingham Birmingham Alabama USA.
ORCID-Profile: Ralph D Sanderson
Förderung
- NCI NIH HHS
- Israel Cancer Association
- Israel Science Foundation
- National Institutes of Health
Zitieren
APA
Vlodavsky, I., Kayal, Y., Hilwi, M., Soboh, S., Sanderson, R. D., & Ilan, N. (2023). Heparanase—A single protein with multiple enzymatic and nonenzymatic functions. Proteoglycan Research. https://doi.org/10.1002/pgr2.6
Vancouver
Vlodavsky I, Kayal Y, Hilwi M, Soboh S, Sanderson RD, Ilan N. Heparanase—A single protein with multiple enzymatic and nonenzymatic functions. Proteoglycan Research. 2023. doi:10.1002/pgr2.6
BibTeX
@article{Vlodavsky2023,
author = {Vlodavsky, Israel and Kayal, Yasmin and Hilwi, Maram and Soboh, Soaad and Sanderson, Ralph D and Ilan, Neta},
title = {Heparanase—A single protein with multiple enzymatic and nonenzymatic functions},
journal = {Proteoglycan Research},
year = {2023},
doi = {10.1002/pgr2.6}
}
EUVIMED